These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 34954213)

  • 21. Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients.
    Massa F; Cremoni M; Gérard A; Grabsi H; Rogier L; Blois M; Couzin C; Hassen NB; Rouleau M; Barbosa S; Martinuzzi E; Fayada J; Bernard G; Favre G; Hofman P; Esnault VLM; Czerkinsky C; Seitz-Polski B; Glaichenhaus N; Sicard A
    EBioMedicine; 2021 Nov; 73():103679. PubMed ID: 34763205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients - Implications for the omicron variant: Correspondence.
    Peled Y; Patel JK; Afek A; Mandelboim M
    J Heart Lung Transplant; 2022 Nov; 41(11):1649-1650. PubMed ID: 35961828
    [No Abstract]   [Full Text] [Related]  

  • 23. Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine : Secondary Analysis of a Randomized Trial.
    Kumar D; Ferreira VH; Hall VG; Hu Q; Samson R; Ku T; Ierullo M; Majchrzak-Kita B; Tomlinson G; Gingras AC; Humar A
    Ann Intern Med; 2022 Feb; 175(2):226-233. PubMed ID: 34807716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune Response after SARS-CoV-2 Vaccination in Kidney Transplant Patients.
    Vaiciuniene R; Sitkauskiene B; Bumblyte IA; Dalinkeviciene E; Ziginskiene E; Bagdonas D; Augliene R; Petruliene K; Bagdziuniene I; Skarupskiene I; Stankuviene A; Sauseriene J; Macinskas S; Valius L
    Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946272
    [No Abstract]   [Full Text] [Related]  

  • 25. Severely impaired humoral response against SARS-CoV-2 variants of concern following two doses of BNT162b2 vaccine in patients with systemic lupus erythematosus (SLE).
    Mageau A; Ferré VM; Goulenok T; Charpentier C; Delory N; Francois C; Houhou-Fidouh N; Papo T; Descamps D; Sacre K
    Ann Rheum Dis; 2022 Aug; 81(8):1194-1196. PubMed ID: 35396228
    [No Abstract]   [Full Text] [Related]  

  • 26. Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay.
    Kato H; Miyakawa K; Ohtake N; Go H; Yamaoka Y; Yajima S; Shimada T; Goto A; Nakajima H; Ryo A
    J Infect Chemother; 2022 Feb; 28(2):273-278. PubMed ID: 34857462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
    Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
    EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus: No cause for alarm.
    Mossad SB
    Am J Transplant; 2021 Aug; 21(8):2908. PubMed ID: 33998136
    [No Abstract]   [Full Text] [Related]  

  • 29. Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients.
    Benning L; Klein K; Morath C; Bartenschlager M; Kim H; Buylaert M; Reineke M; Töllner M; Nusshag C; Kälble F; Reichel P; Schnitzler P; Zeier M; Süsal C; Bartenschlager R; Schaier M; Speer C
    Front Immunol; 2022; 13():840136. PubMed ID: 35309320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine.
    Gallais F; Gantner P; Planas D; Solis M; Bruel T; Pierre F; Soulier E; Rossolillo P; Fourati S; Sibilia J; Schwartz O; Fafi-Kremer S
    Front Immunol; 2022; 13():790212. PubMed ID: 35281046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Humoral Immune Response to BNT162b2 Vaccine Is Associated With Circulating CD19+ B Lymphocytes and the Naïve CD45RA to Memory CD45RO CD4+ T Helper Cells Ratio in Hemodialysis Patients and Kidney Transplant Recipients.
    Duni A; Markopoulos GS; Mallioras I; Pappas H; Pappas E; Koutlas V; Tzalavra E; Baxevanos G; Priska S; Gartzonika K; Mitsis M; Dounousi E
    Front Immunol; 2021; 12():760249. PubMed ID: 34925330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Levels of SARS-CoV-2 Specific Antibodies in Human Milk Following Vaccination.
    Juncker HG; Mulleners SJ; van Gils MJ; de Groot CJM; Pajkrt D; Korosi A; van Goudoever JB; van Keulen BJ
    J Hum Lact; 2021 Aug; 37(3):477-484. PubMed ID: 34176363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected.
    Gidari A; Sabbatini S; Bastianelli S; Pierucci S; Busti C; Monari C; Luciani Pasqua B; Dragoni F; Schiaroli E; Zazzi M; Francisci D
    J Infect; 2021 Oct; 83(4):467-472. PubMed ID: 34320390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protection against SARS-CoV-2 Variants with COVID-19 Vaccination in Kidney Transplant Recipients.
    Bertrand D; Candon S
    Clin J Am Soc Nephrol; 2022 Jan; 17(1):3-5. PubMed ID: 34937770
    [No Abstract]   [Full Text] [Related]  

  • 36. A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response.
    Masset C; Kerleau C; Garandeau C; Ville S; Cantarovich D; Hourmant M; Kervella D; Houzet A; Guillot-Gueguen C; Guihard I; Giral M; Dantal J; Blancho G
    Kidney Int; 2021 Nov; 100(5):1132-1135. PubMed ID: 34474075
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy of anti-SARS-CoV-2 monoclonal antibody prophylaxis and vaccination on the Omicron variant of COVID-19 in kidney transplant recipients.
    Bertrand D; Laurent C; Lemée V; Lebourg L; Hanoy M; Le Roy F; Nezam D; Pruteanu D; Grange S; de Nattes T; Lemoine M; Candon S; Guerrot D
    Kidney Int; 2022 Aug; 102(2):440-442. PubMed ID: 35618097
    [No Abstract]   [Full Text] [Related]  

  • 38. Waning humoral immune response to the BNT162b2 vaccine in heart transplant recipients over 6 months.
    Peled Y; Ram E; Mandelboim M; Lavee J; Sternik L; Segev A; Wieder-Finesod A; Halperin R; Indenbaum V; Levy I; Patel J; Raanani E; Lustig Y; Rahav G
    Am J Transplant; 2022 Jul; 22(7):1931-1932. PubMed ID: 35150072
    [No Abstract]   [Full Text] [Related]  

  • 39. COVID-19 vaccine does not alter panel reactive antibody or flow cytometric cross match in kidney transplant candidates.
    Kumar D; Kimball P; Gupta G
    Transpl Immunol; 2021 Dec; 69():101469. PubMed ID: 34536553
    [No Abstract]   [Full Text] [Related]  

  • 40. Development and longevity of antibodies against SARS-CoV-2 in kidney transplant recipients after symptomatic COVID-19.
    Bajpai D; Shah D; Bose S; Deb S; Gandhi C; Modi T; Rao N; Kumar K; Saxena N; Katyal A; Patil A; Thakare S; Pajai AE; Nataraj G; Jamale TE
    Transpl Infect Dis; 2021 Aug; 23(4):e13646. PubMed ID: 34028939
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.